Introduction
Classification | I | II | III |
---|---|---|---|
1979 | Histologic sub-types included meningotheliomatous, fibrous, transitional, psammomatous, angiomatous, haemangioblastic*, haemangiopericytic*, papillary, and anaplastic. Six histologic parameters, each graded 0–3 points, with the overall score below determining the grade of the tumour: 1. Loss of architecture 2. Increased cellularity 3. Nuclear pleomorphism 4. Mitotic figures 5. Focal necroses 6. Brain infiltration (present =3, absent =0) | ||
0–2 points | 3–6 points | 7–11 points | |
1993 | Histologic sub-types added included microcystic, secretory, clear cell, chordoid, lymphoplasmacytic, metaplastic, atypical. Haemangioblastic and haemangiopericytic sub-types removed. | ||
2000 | 1. Histological sub-type 2. Lack of anaplastic features | 1. Choroid / clear cell histologic sub-type 2. 4–19 mitosis per ten high-power field (HPF) 3. Three or more of 5 features (small cell change, increased cellularity, prominent nucleoli, sheet-like growth, or necrosis) | 1. Rhabdoid (added to classification) / papillary histologic sub-type 2. Histological picture of frank malignancy resembling carcinoma / melanoma / high grade sarcoma 3. >20 mitosis per ten HPF |
2007 | Fourth criteria added: 4. Brain infiltrative and otherwise benign meningiomas |
Methods
Search strategy
Diagnosis | Modality | Imaging Measurement | Outcome Measure |
---|---|---|---|
Meningioma | Magnetic Resonance Imaging | Grow* | Disease Progression |
Meningioma* | Tomography, X-Ray Computed | Morpholog* | Disease-Free Survival |
MRI | Volum* | Prognosis | |
MR | Imaging feature* | Survival | |
Magnetic Resonance Imaging | Recurrence | ||
CT | Neoplasm Grading | ||
Computed Tomography | Histology | ||
Histolog* | |||
Histopatholog* | |||
Prognosis | |||
Survival | |||
Recurrence | |||
Anaplastic Transformation |
-
Study design: Randomised controlled trials, controlled clinical trials, prospective and retrospective observational studies were included conditional upon a sample size > 10 patients from the population of interest. We excluded studies with smaller sample sizes, such as case reports and case series, on the grounds of a potential publication bias risk. Only full articles in English language were included, with articles in other languages, conference abstracts and grey literature excluded.
-
Population: All studies including human subjects with a meningioma.
-
Intervention: Patients underwent imaging with accompanied volumetric growth analysis.
-
Outcome: All studies investigating correlation rates of growth analysis with histological diagnosis, progression-free and overall survival, recurrence rate and rates of anaplastic transformation were included.
Results
Study | Population (n, sex, age, histology) | WHO Classification | Method Used for Volumetric Calculation | Doubling time (mean days) | Outcome measure (histology, recurrence) | Findings |
---|---|---|---|---|---|---|
Jääskeläinen et al. 1985[10] | 43 (14 M, 29 F), mean age 47 years (range 16–65) Benign – 24 Atypical – 12 Malignant - 7 | Corresponding to 1979 grading | Post-operative recurrence after radical removal measured via CT - area of tumour measured using computed planimeter and multiplied by slice thickness. | Grade I - 415 (range 138–1,045) Grade II - 178 (range 34–551) Grade III - 205 (range 30–472) | Compared to initial resection, 4 benign tumours became atypical and 4 anaplastic tumours became malignant. | Highly significant difference between grade I and grade II-III (Kruskal-Wallis one-way ANOVA p < 0.001), but not between grades II and III. Correlation between the mitotic index and the doubling time highly significant (Spearman rank correlation coefficient r = − 0.519, p < 0.001). Atypical meningiomas tend to grow quasi-exponentially. 23/31 asymptomatic meningiomas had already passed the inflection point prior to diagnosis. |
Nakamura et al. 2005[13] | 36 (10 M, 26 F) Grade I – 33 (7 M, 26 F. Mean age 53.14, range 33–79) Grade II - 3 (3 M. Mean age 45.5, range 37–60) | 2000* | Post-operative with remnant tumours determined using areas measured on MRI / CT using NIH image programme (Scion image J) multiplied by slice thickness. Each volume measured three times, and the mean value calculated. | Grade I = 1908 (median) Grade II = 204 (median) | Mean absolute annual growth rate: Grade I =1.51 cm3/year Grade II = 23.3 cm3/year | Growth rates may wary widely even among Grade I meningiomas. Growth rates for younger patients and Grade II meningiomas are significantly higher. Hypo or iso-intense T2 signals and/or presence of calcification on MRI correlate with a lower growth rate. |
Nakasu et al. 2005[15] | 20 (5 M, 15 F), median age 55 Grade I – 9 Grade II – 4 Histology not available – 7 | 2000 | Pre-operative volumes determined using areas measured on MRI / CT using National Institutes of Health (Bethesda, MD) Image 1.62 multiplied by slice thickness. Each volume measured three times, and the mean value calculated. | Benign – 2,198 Atypical – 322 Incidental – 3,223 | Grade I – 8 regrowth, 1 recurrence Grade II – 1 regrowth, 3 recurrence | Growth curves of atypical meningiomas fitted better to the exponential curve (R > 0.94). Although post-resection re-growth was faster than pre-resection in three patients, this was not statistically significant (Wilcoxon matched-pairs test, p = 0.14). Meningiomas without calcification are likely to grow exponentially. |
Nakasu et al. 2011[16] | 52 (13 M, 39 F), median age 57.6 31 – Asymptomatic 21 – Post-operative (Grade I – 15, Grade II – 6) | 2007 | Asymptomatic and post-operative volumes determined using areas measured on MRI / CT using National Institutes of Health (Bethesda, MD) Image 1.62 multiplied by slice thickness. Each volume measured three times, and the mean value calculated. | N/A | One benign tumour enlarged about 8 times during the first 79 months. | Atypical meningiomas unlikely to pass point of tumour growth deceleration compared with benign meningiomas (log-rank test, p = 0.04). No difference of patient’s age at inflection point between symptomatic and asymptomatic meningiomas. Benign meningiomas may pass the inflection point and approach their plateau volume in the long run, while atypical meningiomas are not likely to do so. |
Volumetric calculation methods
Histology grades
Mean growth rates and tumour doubling time
Other findings
Study | Population (n) | Method Used for Volumetric Calculation | Mean tumour growth rates (cm3) | Doubling time | Outcome measure (histology, recurrence) | Findings |
---|---|---|---|---|---|---|
Nakamura et al. 2003 [13] | 41 patients (4 M, 37 F) Mean age 60.9 years (range 33–84) Mean follow-up 43 months (range 6–105) | Post-contrast CT or MRI scans with 3–7 mm thick slices. Volume calculated using the NIH image program (Scion Image J). | Annual growth rate absolute 0.03–2.62 cm3, relative 0.48–72.8% (mean 14.6%). | Mean 21.6 years (1.27 to 143.5 years) | Growth rates correlated with patient age, radiological features including presence of calcification and presence of hyperintensity, and need for surgical intervention. | Tumour size moderate positive correlation with absolute annual growth rate, moderate negative correlation with relative annual growth rate, and no correlation with tumour doubling time. Age was the only predictive factor that correlates with growth. Presence of calcification or hypointense / isointense T2 signals associated with lower tumour growth rate and a longer tumour doubling time. |
Evers et al. 2015 [5] | 210 NF2- associated meningiomas, 21 (8 M, 13 F) mean age 28.48 Mean follow-up = 5.5 years Tumour location:Skull base - 85 Convexity - 31 Other location −91 | The tumours are manually marked on MRI scans using Brainlab software iPlan Cranial 2.6.1 on each MRI scan. Localisation of the tumours were done by experienced neurosurgeon or radiologist. | Skull base - 0.21 Convexity - 0.09 Other - 0.08 | N/A | Growth rates correlated with tumour locations (skull base, convexity and ‘other’ [parasagittal, falx, tentorial, intraventricular, intraorbital] meningiomas) | Skull base tumours have a higher absolute growth rates compared to convexity and ‘other’ meningiomas |
Oya et al. 2011 [18] | 273 meningiomas (53 M, 220 F) in 244 patients.Mean age 60.5 years | The contour of each tumour were manually traced on each slice image using freehand tools on ImageJ version 1.43. The volume of the tumours were calculated by multiplying tumour areas with the slice thickness of the image. | N/A | N/A | Growth rates correlated with the age of patients and radiological features such as presence of calcification, peritumoural oedema, T2 Hyperintensity and initial tumour diameter | Absence of calcification, presence of T2 hyperintensity, age 60 and younger, initial diameter greater than 25 mm, and oedema associated with higher annual growth rates. Volumetric growth rates observed in 74% of cases (114/154) |
Hashiba et al. 2009 [6] | 70 (9 M, 61 F), 7 excluded. Mean age - 61.6. Mean follow-up 39.3 months. Growth group = 44. No growth = 26 | Using the Scion Image for Windows (Scion Corp), the enhanced area of the tumours were calculated by manually tracing the boundaries of each tumour and multiplying the sum enhanced area of tumours with the slice thickness of the MRI images. | Linear group - 14.87%. Exponential - 25.5%. Other’- 15.53% | Mean tumour doubling time = 2808 days (range 390 to 7,020) | Growth rates correlated with patient demographics such as age and gender and radiological features such as initial tumour volume, location, T2 signal intensity and peritumoral oedema. | Growth <15% considered measurement error Presence of calcification distinguished tumour growth group from non-growth group There were no significant difference in gender, age, initial tumour volume, tumour location, peritumoral oedema and T2 signal hyperintensity when comparing growth group with non-growth group |
Firsching et al. 1990 [6] | 17 (3 M, 14 F), Age range 46–83. Histology result available in one case but grade not reported. | Tumour areas were measured by planimeter and volumes were calculated by multiple scale-adjusted tumour areas in squared millimeters with the distance between adjacent CT or MRI scans. | Annual growth rates ranged from 0.5% to 21%, median of 3.6% | N/A | Growth rates correlated with patients’ age, duration of follow-up and initial tumour volume | Tumour growth rate not related to age and there was no relationship between growth rates and initial tumour volume or follow-up period |
Chang et al. 2012 [2] | 31 patients (mean age 62.7) Median follow-up - 4.1 years | Volumetric measurements were performed on T1 post-contrast axial images using the semi-automated user-assisted tumour volume measuring feature of Vitrea Medical Imaging software. Tumour volumes were converted to diameter using the formula (Diameter = (2 x Volume)/3 | Perimetric method - mean growth rate = 15.2% [0.7 mm/year] (significant growth in 19 patients) Diameter method - mean growth rate = 5.6% [0.8 mm/year] (significant growth in 12 patients) | Perimetric method = 4891 days Diametric method = 6533.5 days | Growth rates using perimeter method and diametric method were directly compared. Growth rates were also correlated with patients’ age and radiological features such as tumour location, initial tumour volume, peritumoral oedema and length of follow-up | Measurement using perimeter method showed a significantly higher annual growth rate and lower tumour doubling time when compared to the diameter method (p < 0.01). Age at diagnosis, tumour location, initial tumour volume, length of follow-up, oedema, irregular margins did not distinguish growing from non-growing tumours. |
Hashimoto et al. 2012 [7] | 110 patients (17 M, 93 F), mean age =66.8 mean follow-up = 46.9 years 113 Incidentally-discovered meningiomas 38 Skull base, 75 non-skull base meningiomas | Using the Scion Image for Windows (Scion Corp), the enhanced area of the tumours were calculated by manually tracing the boundaries of each tumour and multiplying the sum enhanced area of tumours with the slice thickness of the MRI images. | 15/38 SB showed growth (1.2 cm3/year) - mean growth 25.56% 56/78 Non-SB showed growth (1.15 cm3/year) - mean growth 94.83% | SB - 4,824 days Non- SB - 3,334.5 days | Growth rates in skull base versus non-skull base were directly compared and also correlated with MIB-1 index | Tumour doubling time was significantly lower (p = 0.008) and percentage of growth (p = 0.002) was significantly higher in non-skull base meningiomas. MIB-1 index was significantly lower in skull base tumours (p = 0.013). Mean MIB-1 index was significantly higher in male with non-skull base tumours (p = 0.021) |
Yoneoka et al. 2000 [25] | 37 patients (5 M,32 F) | Volumes were calculated from CT or MRI scan of 5 mm thickness by using the US National Institute of Health (NIH) image programme. The annual growth rates of the tumours based on the difference in tumour volume between the latest and initial scans divided by the time-interval of the follow-up period | 9/37 patients showed growth (>1 cm3/year) Mean tumour growth in these patients [5.3 +/− 2.1 cm3/year] | N/A | Growth rates correlated with demographics such as age and gender and pre-operative radiological features such as tumour location, initial tumour volume, mass effect and calcification. | Tumour growth significantly higher in younger patients (p = 0.042) and in patients with higher initial tumour volume (p = 0.042). No significant difference between volumetric tumour growth and gender or length of follow-up. |
Ide et al. 1995 [9] | 12 patients (4 M, 8 F), mean age = 60.7 years Grade I Meningiomas | Using the planimeter (Ushikata X-plan 360d; Ushikata Inc., Tokyo), the tumour volume was measured by multiplying the sum area of tumours with slice thickness (5 mm). | 41.425 /12 = 3.452 | 3084.08 days (range 197–7943) | Growth rates correlated with proliferating cell nuclear antigen (PCNA) immunostaining | There is a significant inverse relationship between PCNA indexes and tumour doubling times (p = 0.003). Meningiomas with >1% of PCNA staining indexes have shorter tumour doubling times of <5 years. |
Zeidman et al. 2008 [26] | 21 patients (7 M, 14 F), mean age = 61.0 years Mean follow-up = 3.64 years | Tumour volumes were calculated through serial MRI scans using ellipsoid formula = (AxBxC)/2 where a, b and c represent the three perpendicular axes of each tumour. | Relative growth rate =5.82%/year Relative growth diameter = 2.00%/year | N/A | Growth rates correlated with demographics such as age and gender, radiological characteristics such as tumour location, calcification, T2-signal intensity on MRI, dural tail, mass effect and midline shift) | There was a significant difference between the mean relative volumetric and planimeter growth rate (p < 0.0001). No significant association between tumour location, age, gender, radiological characteristics and volumetric growth rates. |
Dirks et al. 2012 [3] | NF2- associated meningiomas. 13 patients (139 meningiomas),unclear about exact demographics | The tumour volumes were calculated using the ellipsoid formula (AxBxC)/2 on serial post-contrast T1-weighted MRI imaging. | Mean = 0.4 | N/A | Correlated with demographics such as age, gender, Karnofsky Perfomance Scale (KPS) and family history of NF2 and radiological findings such as T2 signal intensity, tumour location, presence of peritumoral cyst, peritumoral oedema and duration of follow-up | A younger age at onset (p = 0.01) and female gender (p = 0.05) were associated with an increased volumetric growth rate of meningiomas. NF2-associated tumours demonstrate a saltatory growth pattern. |
Jung et al. 2000 [11] | 38 Subtotally resected petroclival meningiomas. Male : Female ratio = 5.33. Median age = 47.6 [15–63 years] | The tumour volumes were calculated using the ellipsoid formula (A × B × C)/2 on MRI / CT scans. | Mean = 4.94 cm3/year | 2906 days (range 114–8918) | Growth rates correlated with patients’ age, gender, onset of menopause, tumour size, duration of symptoms, Karnofsky Performance Scale (KPS), post-operative neurological deficits, extent of removal, lobular growth pattern, and involvement of vertebrobasilar artery. | Tumour growth rate is significantly slower in older patients (>50 y). Tumour progression rate in patients with subtotal resection is 42%. Reoperation and/or radiotherapy produced good results in patients with progressive disease. |